Express Scripts turning prescription discount business into nonprofit

NewsGuard 100/100 Score
Anticipating "more people will need access to discount prescriptions no matter what ultimately happens in Washington" with health reform, Express Scripts' Rx Outreach program will become a nonprofit, the St. Louis Post-Dispatch reports. "Heading the new effort is Michael R. Holmes, executive vice president of Express Scripts. He says the change in status will help one of the largest pharmacy benefit management companies in North America extend its reach to the country's poor."

Holmes said "by increasing the percentage of drugs donated, we would be able to further lower the costs for low-income patients. We could start developing alliances with health care organizations and associations to raise awareness among the patients they serve. And we could customize programs for free clinics to enable them to serve patients better. We have not seen other major pharmacy benefit managers offer a similar service model or establish nonprofit organizations to address this need." Families and people who earn up to 300 percent of the federal poverty line will be eligible to receive more than 400 medications at a rate of $20 for a 180-day supply (Moore, 2/18).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common challenges when seeking market access for rare disease therapies